Oxidative Phosphorylation Regulation And Neuroprotection In Optic Neuropathies
Funder
National Health and Medical Research Council
Funding Amount
$430,231.00
Summary
We have shown clear differences in the mitochodria, cellular organelles that generate energy, between optic atrophy patients who have good vision and those of patients who have poor vision. We believe that these changes represent a compensation mechanisms that preserves mitochondrial energy production and protects optic nerve cells. This study will characterize these differences further with the aim of identfying new treatments for preventing nerve loss and preserving vision.
Genetic Determinants Of Inherited Optic Neuropathies
Funder
National Health and Medical Research Council
Funding Amount
$249,750.00
Summary
Glaucoma is a slowly progressive visual disorder of the optic nerves often but not always associated with elevated pressure in the eyes. There is a strong genetic component. It is estimated to affect in excess of 60 million people worldwide with more than 6 million of those blind in both eyes. It is the second commonest cause of visual impairment in the developed world, and is present in up to 10% of the population by age 90. Numbers of affected patients in Australia are expected to double in th ....Glaucoma is a slowly progressive visual disorder of the optic nerves often but not always associated with elevated pressure in the eyes. There is a strong genetic component. It is estimated to affect in excess of 60 million people worldwide with more than 6 million of those blind in both eyes. It is the second commonest cause of visual impairment in the developed world, and is present in up to 10% of the population by age 90. Numbers of affected patients in Australia are expected to double in the next 30 years. Current methods of early detection and treatment are often inadequate, and associated visual loss is irreversible. There is a strong need for greater understanding of the disease process and new strategies to prevent and treat visual loss. Two less common causes of untreatable optic nerve blindness are Leber Hereditary Optic Neuropathy (LHON) and autosomal dominant optic atrophy (ADOA) which occur in younger age groups than most cases of glaucoma, and hence sufferers may experience substantial physical, emotional and economic hardship. Over a 10 year period we have seen large numbers of patients with all three eye conditions and have developed a powerful study to determine the genes which cause optic nerve blindness and their relative importance. The research is gathering momentum and the genetics of all 3 conditions are now partly understood. This project seeks to analyse a new major glaucoma gene (Optineurin) in our Australian population and to try to understand the way in which a number of genes interact to cause blindness in some patients but not others. This work will lead to greater understanding of these causes of blindness and is likely to lead to new screening tests to know who is at most risk, and the opportunity to develop and test new treatments targeted to the underlying genetic problem.Read moreRead less
OXPHOS Upregulation To Preserve Vision In Leber's Hereditary Optic Neuropathy
Funder
National Health and Medical Research Council
Funding Amount
$496,874.00
Summary
Leber's Hereditary Optic Neuropathy (LHON) is a devastating blinding disease that preferentially affects young men. Sufferers have normal vision until teenage years or their twenties when a rapid loss of vision occurs that results in permanent blindness. It is caused by genetic changes in the mitochondrial DNA that we inherit from our mothers. The mitochondria are the cells' energy generators. We aim to use molecules similar to female hormones to boost energy as a new treatment to preserve visio ....Leber's Hereditary Optic Neuropathy (LHON) is a devastating blinding disease that preferentially affects young men. Sufferers have normal vision until teenage years or their twenties when a rapid loss of vision occurs that results in permanent blindness. It is caused by genetic changes in the mitochondrial DNA that we inherit from our mothers. The mitochondria are the cells' energy generators. We aim to use molecules similar to female hormones to boost energy as a new treatment to preserve vision in at-risk LHON individuals.Read moreRead less
Cutting Through Complexity: The Promise Of Biomarkers To Discover, Diagnose, And Treat Antibody-associated Demyelination
Funder
National Health and Medical Research Council
Funding Amount
$438,768.00
Summary
Patients with damage to myelin, the sheath around nerve cells in the brain, have “demyelinating disorders” which can result in severe disability including blindness and paralysis. In some patients, their immune system mistakenly targets certain proteins in the brain. This research project will identify new targets in currently undiagnosed patients, increase our understanding of underlying disease processes, and evaluate optimal treatment strategies in these patients to improve their outcomes.
Optic Nerve Head Structure And Genetic/environmental Associations: A Population-based SD-OCT Study
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
My research project combines two powerful new technologies, spectral domain-optical coherence tomography and the genome-wide association study, to investigate the physical and genetic characteristics of the optic nerve head in humans. Results from this work will help identify new glaucoma risk genes, increasing sensitivity and specificity for predicting glaucoma and expand our understanding of the disease mechanism allowing for the development of new treatments.
Non-invasive Retinal Vein Pulsation Pressure Measurement: A New Assessment Of Glaucoma Treatment.
Funder
National Health and Medical Research Council
Funding Amount
$557,666.00
Summary
Glaucoma is the second most common cause of blindness. It is a slowly degenerating disease and the level of treatment required is difficult to predict. At present there is no way of knowing whether the eye is receiving inadequate treatment. We have shown that retinal vein pulsation pressure measurements are an indicator of the likelihood of glaucoma progression. Our proposed studies hope to demonstrate for the first time that it is feasible to determine the appropriate treatment level for indivi ....Glaucoma is the second most common cause of blindness. It is a slowly degenerating disease and the level of treatment required is difficult to predict. At present there is no way of knowing whether the eye is receiving inadequate treatment. We have shown that retinal vein pulsation pressure measurements are an indicator of the likelihood of glaucoma progression. Our proposed studies hope to demonstrate for the first time that it is feasible to determine the appropriate treatment level for individual patients.Read moreRead less
Development Of A Magnetic Resonance Imaging (MRI) Platform To Evaluate Neuroprotective And Regenerative Therapies In MS
Funder
National Health and Medical Research Council
Funding Amount
$116,667.00
Summary
Multiple Sclerosis (MS) involves inflammation and damage to nerve cells. New therapies are needed to minimize and reverse nerve cell damage. Currently, ways to judge the benefit of these therapies are primitive. We propose that assessing the benefits of these treatments in optic neuritis (inflammation of the eye nerve) is the way forward but first, we need to develop reliable tests to measure these treatments. This application proposes to use magnetic resonance imaging (MRI) for this purpose.
Boosting Mitochondria- A New Approach For Protecting The Aging Optic Nerve In Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$391,784.00
Summary
Increasing age is a major risk factor for neurodegeneration. We have recently shown that subjecting mice to intermittent periods of fasting improves mitochondrial function in the retina and reverses age-related decline in optic nerve vulnerability to injury. This project now aims to investigate key molecular pathway for restoring mitochondria and from this attempts to find more palatable therapeutic strategies for protecting the optic nerve from injury.